Albert (Gus) Davis, MD
The primary goal of our research is to increase our understanding of the basic pathophysiological mechanisms underlying protein aggregation and neurodegeneration in synucleinopathies in order to pave the way for improved diagnostic tests and disease-modifying treatments for these illnesses.
Rajat Dhar, MD, FRCPC
The Dhar lab seeks to leverage data and image-driven approaches to understand the heterogeneity of human responses to severe brain injuries.
Michael N. Diringer, MD
All NNICU physicians have specialized research interests directed at improving the care we provide our patients. A unique aspect of this facility is that it is the only Neuro-ICU in the country with a positron emission tomography (PET) scanner located on site.
Nico U.F. Dosenbach, MD, PhD
Plasticity is one of the hallmark features of the human brain. Use-driven plasticity is critically important for typical development as well as recovering from brain injury. Thus, the overarching goal of our research is to better understand use-driven brain plasticity.
Lawrence N. Eisenman, MD, PhD
The Eisenman lab's primary research interest in the role of GABA receptors both in the normal physiology of the brain and in pathological states, particularly epilepsy. GABA is the major inhibitory neurotransmitter in the central nervous system, and dysfunction in the GABA system is a major component of the pathology of epilepsy.
Anne Fagan, PhD | Suzanne E. Schindler, MD, PhD
The Fluid Biomarker Core has studied Alzheimer disease from multiple angles for more than 20 years. Currently the lab focuses on fluid biomarkers of disease with a particular interest in identifying individuals with preclinical and early stage AD. Our laboratory uses enzyme-linked immunosorbent assays (ELISA), bead-based immunoassays, single-molecule counting systems and automated immunoassays to study protein biomarkers in cerebrospinal fluid and plasma.
Research profile — Anne Fagan
Research profile — Suzanne Schindler
Gilbert Gallardo, PhD
Understand the molecular mechanisms that regulate reactive astrocytes and their neurotoxicity in neurodegenerative diseases, including Alzheimer’s disease, by utilizing a combination of biochemistry, molecular biology, cellular models of inflammation and mouse models of neurodegenerative diseases.
Stefanie Geisler, MD
The goal of the Geisler lab is to identify new therapeutic agents that can be translated into relevant treatment strategies for patients suffering from peripheral neuropathies. We integrate genetic data from patients and analysis of patient-derived neurons with information from cell and animal models to gain insight into molecular mechanisms underlying axon degeneration and regeneration.
Christina A. Gurnett, MD, PhD
Christina Gurnett, MD, PhD, has an interest in understanding the genes involved in inherited forms of epilepsy. Her current approach is to study large families with epilepsy or individuals with unusual chromosomal malformations.
David H. Gutmann, MD, PhD
Our laboratory employs numerous complementary experimental platforms, including human induced pluripotent stem cells and novel genetically-engineered mouse strains to define the molecular and cellular pathogenesis of pediatric brain tumors and cognitive dysfunction relative to improved risk stratification and treatment strategies for children affected with these nervous system problems.